Business Wire

WE-ARE-INNOVATION

9.4.2024 07:01:33 CEST | Business Wire | Press release

Share
Innovation Meets Regulation: International Webinar Explored Effective Anti-Smoking Strategies

We Are Innovation hosted the webinar “Innovation Meets Regulation: The 2024 Effective Anti-Smoking Policies Global Index.” This powerful talk embarked on the official start of the campaign dedicated to the launch of the anti-smoking index. The webinar, featuring Members of the European Parliament, regulatory experts, economists, and innovation experts, shed light on the regulatory frameworks regarding anti-smoking policies from the most prominent global authorities in the field.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240408705665/en/

Federico N. Fernández stated, “At We Are Innovation, we work on issues that require innovative approaches and solutions. One area we recognize as having significant potential for improvement is in innovative nicotine products. Our index encompasses a global population of 5.5 billion individuals, giving the ability to see the differences in global anti-smoking policies and windows for improvement.”

Eric Crampton added, “By showcasing the effectiveness of alternative products, the Index provides a new perspective on addressing smoking-related issues. Moving beyond punishing policies, we can advocate for better regulations that offer innovative solutions to combat smoking habits and promote healthier choices across the globe.”

Guy Bentley covered the situation in the US, “Safer e-cigarettes are seen as far more dangerous than regular cigarettes, even in comparison to the state of affairs 10 years ago which is a significant failure. Now we see the consequences of the informational blockage equal to the so-called ‘invisible graveyard’ — while the safer alternative can come to the market, the delay in the decision-making on the side of the officials that prevents, will lead to the deaths of people who could have been saved if the alternative was available.

MEP Johan Nissinen adds on Swedish policies, “With the new government, in Sweden we introduced higher taxes on cigarettes and lower on snus. The new regulations will come in November of this year. Currently, in Sweden the number of smokers is 5,6 percent while in the EU the average rate is ~23 percent.”

Matt Ridley gave a thought on the UK regulations, “I do not smoke myself, nor I vape, but as a person who is interested in innovations, I see the superior innovative product replacing inferior one which comes together with saving a large amount of lives. When considering the risks associated with vaping, it becomes evident that it offers a significantly smaller risk in terms of carcinogens and is a safer alternative. Government’s policy on vaping has led to the opening of the vaping industry in Britain, catering to a large market of individuals seeking to quit smoking.”

“Innovative nicotine products should be accompanied by smart regulations that balance out public health interests and individual freedoms. By embracing a forward-thinking approach, we can effectively address the problem of smoking,” summed up Tetiana Rak.

Learn more about the 2024 Effective Anti-Smoking Policies Global Index at https://antismoking.global/. The recording of the webinar is available at https://youtu.be/qAYcPAq6rh4.

ABOUT WE ARE INNOVATION

We Are Innovation is a dynamic network of individuals and institutions who fervently believe in the power of innovation to drive progress and solve the world’s most pressing problems. With a global presence encompassing over 40 think tanks, foundations, and NGOs, We Are Innovation represents the diverse voices of a global civil society committed to advancing human creativity, embracing new technologies, and promoting innovative solutions. Through our collaborative approach and cutting-edge expertise, we are spearheading transformative change on a global scale. To learn more about our work, visit us at https://weareinnovation.global/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240408705665/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye